Literature DB >> 21705971

Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats.

Paola Cassis1, Nadia Azzollini, Samantha Solini, Marilena Mister, Sistiana Aiello, Daniela Cugini, Pierangela Scudeletti, Elena Gagliardini, Mauro Abbate, Lorenzo Gallon, Giuseppe Remuzzi, Marina Noris.   

Abstract

BACKGROUND: Ischemia/reperfusion (I/R) injury is an important cause of renal graft dysfunction. Increases in cold and warm ischemia times lead to a higher risk of early posttransplant complications including delayed graft function and acute rejection. Moreover, prolonged cold ischemia is a predictor of long-term graft loss in kidney transplant patients.
METHODS: Darbepoetin alfa (DA) and carbamylated nonerythropoietic derivative of erythropoietin (CEPO) protective effects were evaluated in a model of I/R injury after kidney transplantation in both syngeneic and allogeneic combinations. The effects of wortmannin (phosphorylated Akt [p-Akt] inhibitor) administration were also investigated. Serum creatinine was evaluated at 16, 24, 48 hr and at 4 and 7 days posttransplant. Animals were killed 24 hr or 7 days after transplant and kidneys were processed for histological analysis, immunohistochemistry assessment of erythropoietin receptor (EPOR) and β-common chain receptor expression, granulocyte infiltration, nitrotyrosine staining, p-Akt expression, peritubular capillary (PTC) density, apoptosis, antioxidant, and antiapoptotic gene expression.
RESULTS: DA and CEPO significantly reduced serum creatinine, tubular injury, tubular nitrotyrosine staining, and prevented I/R-induced tubular apoptosis, but only when given both to the donor and to the recipient. DA and CEPO cytoprotection was associated with prevention of I/R-induced drop of p-Akt expression in tubuli, and almost complete preservation of capillary density in the tubulointerstitium of the graft. CEPO was more effective than DA in reducing tubular oxidative stress and preserving PTCs.
CONCLUSION: DA and CEPO when given both to the donor and to the recipient, prevented renal graft dysfunction, tubular oxidative stress, and apoptosis after I/R injury in kidney transplantation. Their cytoprotection was mediated by tubular p-Akt activation and PTC density preservation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21705971     DOI: 10.1097/TP.0b013e3182241106

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  14 in total

1.  Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c+F4/80+ Macrophages through IL-1R8 Regulation.

Authors:  Sistiana Aiello; Manuel Alfredo Podestà; Pamela Y Rodriguez-Ordonez; Francesca Pezzuto; Nadia Azzollini; Samantha Solini; Camillo Carrara; Marta Todeschini; Federica Casiraghi; Marina Noris; Giuseppe Remuzzi; Ariela Benigni
Journal:  J Am Soc Nephrol       Date:  2020-01-27       Impact factor: 10.121

Review 2.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

3.  Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial.

Authors:  Kalathil K Sureshkumar; Sabiha M Hussain; Tina Y Ko; Ngoc L Thai; Richard J Marcus
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-28       Impact factor: 8.237

4.  Immunosuppressive effects of erythropoietin on human alloreactive T cells.

Authors:  Paolo Cravedi; Joaquin Manrique; Katherine E Hanlon; Jessica Reid-Adam; Joshua Brody; Praeophayom Prathuangsuk; Anita Mehrotra; Peter S Heeger
Journal:  J Am Soc Nephrol       Date:  2014-03-27       Impact factor: 10.121

5.  PARP inhibition attenuates acute kidney allograft rejection by suppressing cell death pathways and activating PI-3K-Akt cascade.

Authors:  Karoly Kalmar-Nagy; Peter Degrell; Aliz Szabo; Katalin Sumegi; Istvan Wittmann; Ferenc Gallyas; Balazs Sumegi
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

6.  ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury.

Authors:  Willem G van Rijt; Gertrude J Nieuwenhuijs-Moeke; Harry van Goor; Bente Jespersen; Petra J Ottens; Rutger J Ploeg; Henri G D Leuvenink
Journal:  J Transl Med       Date:  2013-01-09       Impact factor: 5.531

Review 7.  Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care.

Authors:  Nimesh S A Patel; Kiran K Nandra; Christoph Thiemermann
Journal:  Crit Care       Date:  2012-07-26       Impact factor: 9.097

8.  Induction of oxidative stress in kidney.

Authors:  Emin Ozbek
Journal:  Int J Nephrol       Date:  2012-04-17

9.  Protective role of recombinant human erythropoietin in kidney and lung injury following renal bilateral ischemia-reperfusion in rat model.

Authors:  Maryam Moeini; Mehdi Nematbakhsh; Mohammad Fazilati; Ardeshir Talebi; Ali Asghar Pilehvarian; Fariba Azarkish; Fatemeh Eshraghi-Jazi; Zahra Pezeshki
Journal:  Int J Prev Med       Date:  2013-06

Review 10.  Erythropoietin Receptor/β Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion.

Authors:  Yuanyuan Wu; Bin Yang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.